D. Van Raemdonck (Leuven, Belgium), C. Ward (Newcastle Upon Tyne, United Kingdom)
Evaluation of the biological effects of atorvastatin in lung transplant recipients
F. Meloni, A. M. Fietta, N. Solari, M. Morosini, E. Pozzi (Pavia, Italy)
|   |
The complex innate and allospecific response in BOS is mirrored in BALF cytokine profile
F. Meloni, M. Morosini, N. Solari, I. Passadore, A. Bardoni, R. Salvini, A. M. Fietta (Pavia, Italy)
| |
The effect of baseline lung function on the determination of time to bronchiolitis obliterans syndrome
C. Burton, M. Iversen, J. Carlsen, C. Andersen, J. Mortensen (Copenhagen, Denmark)
| |
Pre-transplant soluble CD30 is a stronger predictor of BOS than anti-HLA antibodies occurring after lung transplantation
J. M. Kwakkel-van Erp, E. A. van de Graaf, G. D. Nossent, W. G. J. van Ginkel, D. A. van Kessel, J. M. M. van den Bosch, H. G. Otten (Utrecht, Nieuwegein, Netherlands)
| |
RAGE, a marker of alveolar epithelial type I cell injury, predicts impaired alveolar fluid clearance in isolated perfused human lungs
R. Briot, J. Frank, T. Uchida, M. Matthay (Grenoble, France; San Francisco, United States Of America; Tokyo, Japan)
| |
Bronchial airway anastomotic complications after lung transplantation: is it a surgical problem only?
D. Lardinois, I. Inci, S. Korom, C. Eich, R. Speich, A. Boehler, W. Weder (Zurich, Switzerland)
| |
Can we predict development of bronchiolitis obliterans syndrome (BOS) according to parameters of oxidative stress in lung transplant recipients?
J. Musil, R. Davidova, P. Pafko, R. Lischke, J. ¿imonek, J. Chládek (Prague, Czech Republic)
| |
Positive impact of tacrolimus-based immunosuppression after lung transplantation – an analysis of potential risk factors for long-term survival
P. Huppmann, C. Neurohr, B. Samweber, R. Baumgartner, M. El Nounou, G. Zimmermann, F. Ihle, H. Leuchte, P. Ueberfuhr, R. Hatz, L. Frey, J. Behr (Munich, Germany)
| |
Survival outcomes following lung transplantation for cystic fibrosis patients infected with Burkholderia cenocepacia
G. Meachery, L. Archer, A. De Soyza, G. Parry, S. Clark, K. Tocewicz, A. Fisher, J. Lordan, S. Schueler, K. Gould, J. Dark, P. Corris (Newcastle Upon Tyne, United Kingdom)
| |
Exhaled carbon monoxide correlates with airway neutrophilia in patients with chronic allograft dysfunction (BOS) after lung transplantation
C. Cordemans, R. Vos, B. Vanaudenaerde, A. Schoonis, D. Van Raemdonck, L. Dupont, G. Verleden (Leuven, Belgium)
| |
Ribavirin therapy for respiratory syncitial virus infection after lung transplantation
F. Bini, A. Cascina, F. Meloni, C. Lastoria, T. Oggionni (Pavia, Italy)
| |
A single season surveillance study of respiratory viral infections in lung transplant recipients
J. Gottlieb, I. Engelmann, M. Dierich, M. Zühlsdorf, N. Hesse, A. Simon, T. Schulz, T. Welte (Hannover, Germany)
| |
Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser
M. Keller, G. Menges, A. Akkar, J. Behr, C. Herpich, K. Sommerer, J. Seitz (Munich, Germany)
| |